Harbor Capital Advisors’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Harbor Capital Advisors’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$726K	Sell	15,068 -6,475	-30%	-$287K	0.06%	394
2025 Q4	$889K	Buy	21,543 +843	+4%	+$33.8K	0.07%	353
2025 Q3	$804K	Sell	20,700 -50,226	-71%	-$1.63M	0.06%	370
2025 Q2	$1.96M	Sell	70,926 -6,796	-9%	-$173K	0.08%	302
2025 Q1	$1.73M	Sell	77,722 -20,371	-21%	-$419K	0.08%	319
2024 Q4	$1.94M	Buy	98,093 +550	+0.6%	+$12.6K	0.08%	298
2024 Q3	$2.44M	Buy	+97,543	New	+$2.38M	0.11%	267
2024 Q2	–	Sell	-13,142	Closed	-$259K	–	749
2024 Q1	$259K	Buy	+13,142	New	+$257K	0.03%	551

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Harbor Capital Advisors's KNSA Position: Q1 2026 in Review

Harbor Capital Advisors reduced its Kiniksa Pharmaceuticals (KNSA) stake by 30% in Q1 2026, selling an estimated $287K and leaving 15,068 shares worth $726K. The position accounts for 0.06% of the portfolio, ranked #394.

Harbor Capital Advisors first reported a position in KNSA in Q1 2024 and has held it in 8 quarters since. The position peaked at $2.44M in Q3 2024. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

Harbor Capital Advisors held 15,068 shares of Kiniksa Pharmaceuticals worth $726K as of Q1 2026.
Harbor Capital Advisors sold 6,475 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $287K.
Kiniksa Pharmaceuticals made up 0.06% of Harbor Capital Advisors's portfolio in Q1 2026, its #394 holding.
Harbor Capital Advisors first reported a position in Kiniksa Pharmaceuticals in Q1 2024 and has held it in 8 quarters since.
Harbor Capital Advisors's Kiniksa Pharmaceuticals position peaked at $2.44M in Q3 2024.
228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on Harbor Capital Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.